Commercialization at UHN Analysis: $750K Raised
What is Commercialization at UHN?
Research commercialization hub at University Health Network
Location
Toronto, Canada
Employees
11-50
Founded
1999
Product Features & Capabilities
- Ex-vivo lung perfusion technology
- ADELA blood-based cancer diagnostics platform
- TREADWELL THERAPEUTICS cancer immunotherapy
- MEDLY THERAPEUTICS digital health platform for heart failure
- Porphyrin lipid nanoparticle drug delivery system
- Dry electrode technology for rehabilitation
Use Cases
Licensing ex-vivo lung perfusion for transplant availability improvement; Developing ADELA diagnostics for early cancer detection; Commercializing TREADWELL TCR T-cell therapies for cancer; Deploying MEDLY platform for chronic heart failure management; Using porphyrin LNPs to deliver therapeutics with 30–50% greater efficiency than current systems; Applying dry electrode technology to restore movement after stroke or paralysis
How much Commercialization at UHN raised
Funding - $750K
Other Considerations
Acquired Trillium Therapeutics by Pfizer for $2.22B; Acquired BlueRock Therapeutics by Bayer for $1B; Secured $60M financing round for ADELA; Raised $91M Series B for TREADWELL; Formed 10+ start-ups since 2014; 4 years of exit valuations for UHN start-ups since 2018
See something that needs updating? Suggest edits to this profile.